1. Cellulitis: what to measure, how to define? Systematic review of outcomes from cellulitis trials. (16th May 2018) Authors: Sunderkötter, C. Journal: British journal of dermatology Issue: Volume 178:Number 5(2018) Page Start: 1000 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Cellulitis: what to measure, how to define? Systematic review of outcomes from cellulitis trials. (1st May 2018) Authors: Sunderkötter, C. Journal: British journal of dermatology Issue: Volume 178:Number 5(2018) Page Start: 1000 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. European Dermatology Forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes. (9th August 2017) Authors: Knobler, R.; Moinzadeh, P.; Hunzelmann, N.; Kreuter, A.; Cozzio, A.; Mouthon, L.; Cutolo, M.; Rongioletti, F.; Denton, C.P.; Rudnicka, L.; Frasin, L.A.; Smith, V.; Gabrielli, A.; Aberer, E.; Bagot, M.; Bali, G.; Bouaziz, J.; Braae Olesen, A.; Foeldvari, I.; Frances, C. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 31:Number 9(2017) Page Start: 1401 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. European dermatology forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis. (8th August 2017) Authors: Knobler, R.; Moinzadeh, P.; Hunzelmann, N.; Kreuter, A.; Cozzio, A.; Mouthon, L.; Cutolo, M.; Rongioletti, F.; Denton, C.P.; Rudnicka, L.; Frasin, L.A.; Smith, V.; Gabrielli, A.; Aberer, E.; Bagot, M.; Bali, G.; Bouaziz, J.; Braae Olesen, A.; Foeldvari, I.; Frances, C. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 31:Number 10(2017) Page Start: 1581 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. FRI0244 Assessing organ involvement and current symptoms as indicators for disease progression in 3047 patient cohort. (23rd January 2014) Authors: Moinzadeh, P.; Hunzelmann, N.; Krieg, T.; Blank, N.; Fierlbeck, G.; Genth, E.; Kötter, I.; Kreuter, A.; Melchers, I.; Pfeiffer, C.; Müller-Ladner, U.; Riemekasten, G.; Sunderkötter, C. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 396 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Schwere Candida‐Balanoposthitis unter gleichzeitiger Therapie mit Secukinumab und dem Antidiabetikum Empagliflozin (Natrium‐Glukose‐Cotransporter 2 – SGLT2‐Inhibitor). (8th April 2019) Authors: Moldenhauer, I.; Pliquett, R.U.; Kreft, B.; Sunderkötter, C. Journal: Journal der Deutschen Dermatologischen Gesellschaft Issue: Volume 17:Number 4(2019) Page Start: 456 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Severe candidal balanoposthitis on concurrent treatment with secukinumab and the antidiabetic agent empagliflozin (sodium‐glucose cotransporter 2 inhibitor – SGLT2‐inhibitor). (15th March 2019) Authors: Moldenhauer, I.; Pliquett, R.U.; Kreft, B.; Sunderkötter, C. Journal: Journal der Deutschen Dermatologischen Gesellschaft Issue: Volume 17:Number 4(2019) Page Start: 456 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Skin metastases in metastatic uveal melanoma: GNAQ/GNA11 mutational analysis as a valuable tool. (8th July 2013) Authors: Tsianakas, A.; Böhm, M.R.R.; Getova, V.; Metze, D.; Eter, N.; Spieker, T.; Bräuninger, A.; Luger, T.; Schiller, M.; Sunderkötter, C. Journal: British journal of dermatology Issue: Volume 169:Number 1(2013:Jul.) Page Start: 160 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. The Predict Study: low risk for digital ulcer development in patients with systemic sclerosis with increasing disease duration and lack of topoisomerase‐1 antibodies. (1st June 2016) Authors: Hunzelmann, N.; Riemekasten, G.; Becker, M.O.; Moinzadeh, P.; Kreuter, A.; Melchers, I.; Mueller‐Ladner, U.; Meier, F.; Worm, M.; Lee, H.; Herrgott, I.; Pfeiffer, C.; Fierlbeck, G.; Henes, J.; Juche, A.; Zeidler, G.; Mensing, H.; Günther, C.; Sárdy, M.; Burkhardt, H. Journal: British journal of dermatology Issue: Volume 174:Number 6(2016) Page Start: 1384 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. The Predict Study: low risk for digital ulcer development in patients with systemic sclerosis with increasing disease duration and lack of topoisomerase‐1 antibodies. (20th March 2016) Authors: Hunzelmann, N.; Riemekasten, G.; Becker, M.O.; Moinzadeh, P.; Kreuter, A.; Melchers, I.; Mueller‐Ladner, U.; Meier, F.; Worm, M.; Lee, H.; Herrgott, I.; Pfeiffer, C.; Fierlbeck, G.; Henes, J.; Juche, A.; Zeidler, G.; Mensing, H.; Günther, C.; Sárdy, M.; Burkhardt, H. Journal: British journal of dermatology Issue: Volume 174:Number 6(2016) Page Start: 1384 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗